Hutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab

Hutchmed (HCM) and Innovent Biologics “jointly announce that the FRUSICA-2 Phase2/3 clinical trial evaluating fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma in China has met its primary endpoint of progression free survival per RECIST 1.1 as assessed by blinded independent central review. The combination of fruquintinib and sintilimab received conditional approval from the China National Medical Products Administration for the treatment of patients with advanced endometrial cancer with Mismatch Repair proficient tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation, based on data from the FRUSICA-1 study.”